Nippon Shinyaku Co. Ltd. has divulged azaindole compounds acting as mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, multiple sclerosis, rheumatoid arthritis, psoriasis, spinal cord injury, Behçet’s disease, atopic dermatitis and idiopathic pulmonary fibrosis, among others.
Researchers have identified glutathione peroxidase 4 (GPX4) as a therapeutic target in abdominal aortic aneurysm, a vascular disease characterized by permanent and focal dilatation of the abdominal aorta, with a mortality rate of up to 85% in case of rupture.
Aberrant signaling by fibroblast growth factor receptors (FGFRs) drives tumor cell survival and proliferation in several cancers, making them promising therapeutic targets.
Multiple sclerosis (MS) is characterized by persistent inflammation, primarily driven by CNS-resident immune cells like microglia, particularly in the progressive stages. The purinergic P2X7 receptor (P2X7R) is widely expressed on immune cells and is elevated on reactive astrocytes and microglia of MS lesions.
RSS
